End Taxpayer Funding of Gender Experimentation Act of 2025
- Bill Number
- S. 977
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-12: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-05-12T11:03:31Z
AI-Generated Summary
Purpose
The legislation, titled the "End Taxpayer Funding of Gender Experimentation Act of 2025," aims to prevent the use of federal taxpayer funds for procedures related to gender transition. It seeks to define and restrict federal support for medical interventions that change a person's physical characteristics to align with a gender identity different from their biological sex, while allowing such procedures to be covered by non-federal funds.
Key Provisions
- Prohibition on Federal Funding (Title I, Sec. 101): Adds a new Chapter 4 to Title 1 of the United States Code, banning the use of any federal funds (including from trust funds) for "gender transition procedures." This includes:
- Hormonal treatments, such as puberty blockers, supraphysiologic doses of hormones (doses higher than what the body naturally produces), or other drugs to alter sex characteristics.
- Surgical interventions, including castration, hysterectomy, mastectomy, phalloplasty, vaginoplasty, and various cosmetic or reconstructive surgeries to masculinize or feminize features (a comprehensive list of 33 specific procedures is provided).
- Ban on Funding Health Plans Covering These Procedures (Sec. 302): Federal funds cannot support health benefits plans that include coverage for gender transition procedures.
- Restrictions on Federal Facilities and Employees (Sec. 303): Prohibits gender transition procedures in federally owned or operated health facilities (e.g., military hospitals or VA clinics) or by federal employees acting in their official capacity.
- Definitions (Sec. 307):
- "Sex" is defined biologically as male or female based on reproductive systems (e.g., sperm or egg production).
- "Gender transition" refers to changing one's presentation or identification from their biological sex to a different gender identity, potentially involving social, legal, or physical changes.
- Exclusions from "gender transition procedures" include treatments for congenital disorders of sex development (e.g., ambiguous genitalia due to chromosomal issues), complications from prior procedures, life-threatening physical conditions, precocious puberty, or male circumcision.
- Constructions and Exceptions (Secs. 304–306):
- Allows individuals, states, or localities to purchase separate coverage for these procedures using only non-federal funds (no matching federal requirements, like Medicaid contributions).
- Does not restrict non-federal providers from offering such coverage with private funds.
- Permits treatment of infections, injuries, or disorders caused by gender transition procedures, even if the original procedure used federal funds.
- Application to Affordable Care Act (ACA) (Title II, Sec. 201):
- Amends the Internal Revenue Code to deny premium tax credits (subsidies for buying insurance) and cost-sharing reductions under the ACA for plans covering gender transition procedures.
- Denies the small employer health insurance expense credit for plans including such coverage.
- Requires multi-state health plans (offered through ACA exchanges) to comply with the funding ban.
- Allows separate, unsubsidized coverage for these procedures.
- Effective Date: Applies to taxable years and plan years beginning one year after enactment.
Significant Changes to Existing Law
- New Statutory Framework: Creates an entirely new chapter in Title 1 of the U.S. Code dedicated to prohibiting federal funding for gender transition procedures, which did not previously exist in this form.
- Amendments to Tax Code: Modifies Sections 36B (premium tax credits) and 45R (small employer credits) of the Internal Revenue Code to exclude plans covering these procedures from federal subsidies, introducing a specific carve-out not present before.
- ACA Modifications: Alters Section 1334 of the ACA (Public Law 111-148) to enforce the ban on multi-state plans, linking it directly to the new U.S. Code chapter. This expands restrictions on federal support beyond direct appropriations to indirect subsidies.
- No Broader Changes: Does not alter state laws allowing these procedures or private insurance; it only targets federal involvement.
Potential Impacts
- On Government Agencies: Federal health programs (e.g., Medicare, Medicaid, TRICARE, VA health services) would be unable to cover or perform gender transition procedures, requiring agencies like the Department of Health and Human Services (HHS) and Department of Veterans Affairs to revise policies, guidelines, and reimbursements. This could increase administrative costs for compliance and enforcement.
- On Citizens: Transgender individuals relying on federal programs would lose access to taxpayer-funded gender transition care, potentially forcing them to seek private funding or forgo treatment. It may affect an estimated thousands of beneficiaries in programs like Medicaid. Non-transgender individuals and those with qualifying medical conditions (e.g., disorders of sex development) would see no change in coverage for excluded procedures.
- On Healthcare Providers: Federal employees and facilities (e.g., military doctors) could face professional restrictions, while private providers remain unaffected if using non-federal funds. Insurers on ACA exchanges might need to offer separate plans to maintain subsidy eligibility.
- On International Relations: Minimal direct impact, though it could influence U.S. foreign aid health programs or diplomatic discussions on global LGBTQ+ rights by signaling a restrictive domestic policy.
Main Stakeholders Affected
- Transgender Individuals: Primary group impacted, as they may lose federal support for transitioning, affecting access to care in public programs.
- Federal Government Agencies: Including HHS, IRS, VA, and Department of Defense, responsible for implementing bans and handling enforcement.
- Healthcare Providers and Facilities: Especially those federally funded or employed, who must adjust services; private providers can continue offering coverage privately.
- States and Localities: Affected in Medicaid and other programs using federal matching funds; they can still use state-only funds for coverage.
- Insurance Issuers and Employers: ACA marketplace plans and small businesses must comply to retain subsidies, potentially leading to redesigned offerings.
- Individuals with Related Medical Conditions: Protected under exclusions, ensuring continued access for those with biological disorders.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The bill's detailed definitions of "sex" and procedures could invite lawsuits over scope, such as whether certain treatments qualify as "gender transition" versus medically necessary care. It may conflict with existing anti-discrimination laws (e.g., under Title VII or Section 1557 of the ACA, which prohibit sex discrimination in health care) by limiting access based on gender identity.
- Constitutional Implications: Potential challenges under the Equal Protection Clause of the 14th Amendment for discriminating against transgender people, or under the Fifth Amendment's Due Process Clause for restricting medical autonomy. It does not directly implicate free speech (First Amendment) but could indirectly affect gender-affirming care debates.
- Political Implications: As a partisan bill introduced by Republican senators, it reflects ongoing cultural debates on gender identity and federal spending. If enacted, it could set a precedent for restricting funding on social issues, influencing future appropriations and state-federal dynamics, while facing opposition from civil rights groups advocating for transgender healthcare access.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (14)
Sen. Hyde-Smith, Cindy [R-MS], Sen. Cramer, Kevin [R-ND], Sen. Hawley, Josh [R-MO], Sen. Budd, Ted [R-NC], Sen. Graham, Lindsey [R-SC], Sen. Sheehy, Tim [R-MT], Sen. Blackburn, Marsha [R-TN], Sen. Banks, Jim [R-IN], Sen. Wicker, Roger F. [R-MS], Sen. Lee, Mike [R-UT], Sen. Lummis, Cynthia M. [R-WY], Sen. Risch, James E. [R-ID], Sen. Scott, Rick [R-FL], Sen. McCormick, David [R-PA]
Recent Actions
- 2025-03-12: Read twice and referred to the Committee on Finance.
- 2025-03-12: Introduced in Senate
Bill Versions
- End Taxpayer Funding of Gender Experimentation Act of 2025 — issued 2025-03-12 — PDF (14 pages)